PRKCD and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, it has been demonstrated that CDCP1 is overexpressed in CD34+ positive cells of Nilotinib-resistant CML patients with t(9;22), suggesting that CDCP1 can prevent Nilotinib-induced cell death, by cooperating with PKCδ, with its multiple attachment sites [35].